1. Introduction {#sec0005}
===============

Primary liver carcinoma, including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (CCA), is the second leading cause of cancer-related deaths worldwide \[[@bib0005]\]. Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a rare primary liver carcinoma with both HCC and CCA components in one tumor nodule \[[@bib0010], [@bib0015], [@bib0020]\].

Some reports have shown worse prognosis for cHCC-CCA than that for HCC in liver transplantation (LT) \[[@bib0025], [@bib0030], [@bib0035], [@bib0040]\]. However, because of the rarity of cHCC-CCA, few reports have described the outcomes of LT for cHCC-CCA. Therefore, the indications of LT for cHCC-CCA remain controversial. The present study examined four cases at our institute. The research work has been reported in line with the process criteria \[[@bib0045]\].

2. Case presentations {#sec0010}
=====================

2.1. Patients {#sec0015}
-------------

All patients who underwent LT between January 2005 and December 2018 at our institute were enrolled. The study protocol was approved by the Ethics Committee of our institute and performed in accordance with the 1964 Declaration of Helsinki and its later amendments. A total of 835 patients underwent LT, four of whom underwent living donor LT (LDLT) for cHCC-CCA. All four patients had multiple tumor nodules and were diagnosed with HCC preoperatively. One of the multiple tumors turned out to be cHCC-CCA by postoperative pathological examination. The pathological diagnoses were made in accordance with the 2019 World Health Organization (WHO) classification based on hematoxylin and eosin staining \[[@bib0020]\]. The clinical features of the four patients are summarized in [Table 1](#tbl0005){ref-type="table"}.Table 1Clinicopathological features of the four cases with cHCC-CCA.Table 1Case1234Age65626745SexMMFMBackground liver diseaseHCV-LCHBV-LCNASHAlcoholic LCChild-PughC(11)C(11)B(8)C(10)CEA \[ng/mL\]2.43.1511CA19-9 \[U/mL\]4033.134.8\<0.6AFP \[ng/mL\]85.86.72075642.3DCP \[mAU/mL\]845938018Milan criteriaWithinWithin(Beyond→) Within\*BeyondKyoto criteriaWithinWithinWithin(Within→) Beyond\*\*Tumor number (total)323＞10Tumor number (cHCC-CCA)1111Tumor size(cHCC-CCA) \[cm\]1.41.12.13.6Tumor size(maximum) \[cm\]2.91.133.6Recurrence------Multiple liver cancerRecurrence\[month\]------9OutcomeAliveAliveAliveDeathSurvival time\[month\]65661115Cause of death------Liver cancer[^1]

2.2. Case 1: a 65-year-old man {#sec0020}
------------------------------

The patient was referred to our institute for hepatitis C virus-associated cirrhosis with multiple liver tumors in segments 4 and 8. He previously underwent a partial liver resection for HCC. Computed tomography (CT) showed two tumors (maximum size 21 mm) ([Fig. 1](#fig0005){ref-type="fig"}a and b). F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) / CT failed to detect a high standardized uptake value (SUV) tumor. His des-gamma carboxyprothrombin (DCP) and α-fetoprotein (AFP) levels were 84 mAU/mL and 85.8 ng/mL, respectively. His Child-Pugh (C-P) score was grade C (11 points) and his Model for End-stage Liver Disease (MELD) score was 12 points. Since he met the Milan criteria \[[@bib0050]\], LDLT with the right lobe graft was performed. Postoperative pathological examination revealed three tumors ([Fig. 1](#fig0005){ref-type="fig"}c): one of which was diagnosed as cHCC-CCA ([Fig. 1](#fig0005){ref-type="fig"}d--f). The other two tumors were HCC. He lived without tumor recurrence for over five years.Fig. 1The cHCC-CCA nodule in Case 1. The computed tomography (CT) scan shows a tumor in segment 2, which is enhanced in the portal phase (a) and washed out in the late phase (b). This tumor macroscopically appeared solid white (c). Pathological findings indicating that the nodule consists of two components (d): CCA (e) and HCC (f).Fig. 1

2.3. Case 2: a 62-year-old man {#sec0025}
------------------------------

The patient was referred to our institute for hepatitis B virus-associated cirrhosis with multiple HCCs. He had a history of distal gastrectomy for a gastric ulcer at 20 years of age. He had been treated with entecavir hydrate. The patient developed recurrent encephalopathy and esophageal varices hemorrhage in the year before the LT. His C-P score was grade C (11 points) and his MELD score was 16 points. Preoperative examination revealed three liver tumors ([Fig. 2](#fig0010){ref-type="fig"}a and b) that were 20 mm or less in diameter, thereby meeting Milan criteria. Contrast-enhanced magnetic resonance image (MRI) revealed tumors with arterial phase hyper-enhancement and a washed-out appearance, typical of HCC. The preoperative examination also detected ascending colon cancer. Ileocecal resection was performed first. We determined that his cancer was early-stage, and LDLT was performed one month later. Pathological examination showed two viable liver tumors ([Fig. 2](#fig0010){ref-type="fig"}c): one cHCC-CCA ([Fig. 2](#fig0010){ref-type="fig"}d--f) and one HCC. He experienced no recurrences for over five years.Fig. 2The cHCC-CCA nodule of Case 2. The computed tomography (CT) scan shows a small enhanced nodule (white arrow) in the portal phase (a). The nodule is not visible in the late phase (b). cHCC-CCA (white square) (c). Microscopically, the tumor consists of two components: CCA (e) and HCC (f).Fig. 2

2.4. Case 3: a 67-year-old woman {#sec0030}
--------------------------------

The patient had been followed for non-alcoholic steatohepatitis. She underwent a partial hepatectomy for an HCC at 59 years of age and had twice undergone radiofrequency ablation for HCC recurrence. She was referred to our institute for multiple liver tumors with worsening liver function. Preoperative CT examination suggested five tumors with a maximum diameter of 29 mm, thus not meeting Milan criteria ([Fig. 3](#fig0015){ref-type="fig"}a and b). However, her DCP level was 380 mAU/mL, meeting Kyoto criteria (ten or fewer tumors, maximum tumor size of 5 cm or less, and DCP level of 400 mAU/mL or less), as it is an extended criterion for LDLT \[[@bib0055]\]. FDG-PET / CT didn't detect a high SUV tumor, and contrast-enhanced MRI results were typical for HCC. Her C-P score was grade B (8 points). We performed a LDLT using a right liver graft. The postoperative pathological examination revealed three viable tumors with a maximum diameter of 30 mm. Therefore, she retrospectively met Milan criteria. One tumor was cHCC-CCA (21 mm in diameter); the other two were HCC ([Fig. 3](#fig0015){ref-type="fig"}c--f). DCP and AFP levels, which are tumor markers, decreased to within the normal range postoperatively. She lived without tumor recurrence for approximately one year after LDLT.Fig. 3The cHCC-CCA nodule of Case 3. The computed tomography (CT) scan indicates three tumors in portal (a) and late (b) phases. The tumor---indicated by the white arrow---is the cHCC-CCA nodule; the other tumors (arrowheads) are HCC nodules (c). Pathological findings indicate that the nodule consists of two components (d): CCA (e) and HCC (f).Fig. 3

2.5. Case 4: a 45-year-old man {#sec0035}
------------------------------

The patient was referred to our institute for alcoholic cirrhosis with multiple liver tumors. He underwent laparoscopic partial liver resection for HCC five years previously and also received transcatheter arterial chemoembolization for HCC recurrence. The preoperative CT examination revealed five classical HCC tumors ([Fig. 4](#fig0020){ref-type="fig"}a and b). His C-P score was grade C (10 points) and his MELD score was 20 points. The patient's AFP level was 642.3 ng/mL and his DCP level (18 mAU/mL) was within normal limits. His condition met Kyoto criteria and LDLT was performed using a right liver graft. Pathological examination revealed more than ten viable tumors in the recipient\'s liver. The largest tumor was diagnosed as cHCC-CCA (36 mm in diameter) ([Fig. 4](#fig0020){ref-type="fig"}c and e--g); the other tumors were HCCs ([Fig. 4](#fig0020){ref-type="fig"}d). Therefore, the pathological examination revealed retrospectively that his condition met neither Kyoto nor Milan criteria. The postoperative AFP level temporarily dropped to within the normal range; however, nine months after LDLT, his AFP and DCP levels were elevated (18.8 ng/mL and 80 mAU/mL, respectively), and CT examination revealed multiple liver tumors with hypervascularities, suggesting multiple HCC recurrence. He died of liver failure and HCC recurrence 15 months after the LDLT.Fig. 4The cHCC-CCA nodule of Case 4. The computed tomography (CT) scan indicates three tumors in the portal (a) and late (b) phases. The arrow indicates the cHCC-CCA nodule while the arrowheads show HCC nodules. Macroscopically, the cHCC-CCA nodule---indicated by the arrow---is white (c), while the multiple HCC nodules are green (d). The microscopic findings show that the nodule consists of two components (e): CCA (f) and HCC (g), surrounded by a CCA component.Fig. 4

3. Discussion {#sec0040}
=============

The preoperative diagnosis of cHCC-CCA is difficult because it has few specific imaging characteristics \[[@bib0060]\]. The strategy for preoperative diagnosis of cHCC-CCA has been studied before \[[@bib0065], [@bib0070], [@bib0075]\], however, in the present study---in spite of the multimodal preoperative examination (PET/CT, MRI, or tumor markers, etc.)---all four patients received LDLT for preoperative diagnoses of multiple HCC tumors. Postoperative pathological examinations incidentally revealed that one of the multiple tumors was cHCC-CCA and that the remaining tumors were HCC. In this study, the cHCC-CCA characteristics were not captured, even after checking the images retrospectively. If these patients had been diagnosed with cHCC-CCA preoperatively would they have demonstrated indications for LT?

Some studies reported poor outcomes of LT for cHCC-CCA. Analyses based on large-scale data, including the Surveillance Epidemiology and End Results (SEER) and United Network for Organ Sharing (UNOS) databases suggested worse outcomes of LT for cHCC-CCA than for HCC. The analyses also indicated that the therapeutic effects of LT for cHCC-CCA were limited \[[@bib0030], [@bib0035], [@bib0040]\]. However, several reports showed that small cHCC-CCA tumors (2 cm or less), were associated with better prognosis \[[@bib0080],[@bib0085]\]. Therefore, no conclusions have been reached regarding the LT indications for cHCC-CCA.

In general, patients with cHCC-CCA have background liver diseases \[[@bib0090],[@bib0095]\]. Thus, LT for cHCC-CCA theoretically reduces the recurrence rate as well as LT does for HCC. All patients in this case series had serious liver dysfunction. Although the patient with tumors that met neither Millan nor Kyoto criteria relapsed immediately after LDLT, the three patients who met Milan criteria had no recurrence after LDLT. These findings suggested that cHCC-CCA was not an absolute contraindication for LT.

4. Conclusions {#sec0045}
==============

In this series, the patients with cHCC-CCA who met Milan criteria on postoperative pathological examination had no recurrence after LDLT. Thus, cHCC-CCA itself is not a contraindication for liver transplantation in patients with cirrhosis.
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[^1]: \*Case 3 did not meet the Milan criteria preoperatively. However, she met the criteria on the postoperative examination. \*\* Case 4 met Kyoto criteria preoperatively, but did not meet Kyoto criteria on the postoperative examination. M: male, F: female, HCV: hepatitis C virus, HBV: hepatitis B virus, NASH: non-alcoholic steatohepatitis, LC: liver cirrhosis.
